[Asthmatic illness: basic trial treatment by ketotifen (apropos of 48 cases)].
This study draws on 48 Asthma files of which 68.7% were of allergic origin, and has led to the following conclusions: Ketotifene is particularly active on mainly allergic asthma, and 72.7% of the results obtained were good. the younger the asthma, the more effective the product effectiveness is greater where the sickness is recent and the patient not on medication the economy in corticoids is significant: 60% on average, it can attain 100%. On the other hand, the medicine has little effect on mainly non-allergic asthma, such as infectious asthma, late asthma and the recurrence of former asthma, all difficult to treat. One author stresses that results improve as etiological factors diminish. While awaiting the fruit of progress and research in providing other medicine to conclusively conquer asthma, Ketotifene constitutes a new, choice weapon for the therapeutic arsenal ranged against the causes of this sickness.
Hane
A A
AA
Clinique de Pneumophtisiologie Centre Hospitalier de Fann.
Kane/Fall
A M
AM
Ndir
M
M
Ayad
M
M
Badiane
M
M
Kane
P A
PA
D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007665:Ketotifen / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D007665:Ketotifen
Maladie asthmatique: essai de traitement de fond par le kétotifène (A propos de 48 observations).